Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

moxifloxacin

Known as: 1-cyclopropyl--7-(2,8-diazabicyclo(4.3.0)non-8-yl)-6-fluoro-8-methoxy-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid, 1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-((4as,7as)-octahydro-6H-pyrrolo(3,4-b)pyridin-6-yl)-4-oxo-3-quinolinecarboxylic acid, MOXI 
A fluoroquinolone antibiotic with antibacterial activity. Moxifloxacin binds to and inhibits the bacterial enzymes DNA gyrase (topoisomerase II) and… Expand
National Institutes of Health

Related topics

Related topics

39 relations
AmiodaroneAmiodarone hydrochlorideAvelox 400 mg oral tablet includes Avelox ABC PackBacterial Infections
Expand

Broader (3)

Anti-Bacterial AgentsFluoroquinolonesTopoisomerase II Inhibitors

Narrower (5)

AveloxMoxifloxacin hydrochlorideOctegraProflox
Expand

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2020
Highly Cited
2020
Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.
Importance In December 2019, novel coronavirus (2019-nCoV)-infected pneumonia (NCIP) occurred in Wuhan, China. The number of… Expand
  • table 1
  • table 2
  • figure 1
  • table 3
  • table 4
Is this relevant?
Highly Cited
2014
Highly Cited
2014
Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis.
BACKGROUND Early-phase and preclinical studies suggest that moxifloxacin-containing regimens could allow for effective 4-month… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
Highly Cited
2014
Highly Cited
2014
High-dose rifapentine with moxifloxacin for pulmonary tuberculosis.
BACKGROUND Tuberculosis regimens that are shorter and simpler than the current 6-month daily regimen are needed. METHODS We… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2012
Highly Cited
2012
14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial
BACKGROUND New drugs, but also shorter, better-tolerated regimens are needed to tackle the high global burden of tuberculosis… Expand
  • table 1
  • table 2
  • table 3
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2009
Highly Cited
2009
Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis.
RATIONALE Moxifloxacin has potent activity against Mycobacterium tuberculosis in vitro and in a mouse model of antituberculosis… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
Highly Cited
2008
Highly Cited
2008
A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis.
SETTING Current treatment for pulmonary tuberculosis (TB) might be shortened by the incorporation of fluoroquinolones (FQs… Expand
Is this relevant?
Highly Cited
2006
Highly Cited
2006
Inhibitors of NF-κB signaling: 785 and counting
Nuclear factor kappa B (NF-κB) transcription factors regulate several important physiological processes, including inflammation… Expand
  • figure 1
  • table 1
  • table 2
Is this relevant?
Highly Cited
2005
Highly Cited
2005
An epidemic, toxin gene-variant strain of Clostridium difficile.
BACKGROUND Recent reports suggest that the rate and severity of Clostridium difficile-associated disease in the United States are… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
Highly Cited
2004
Highly Cited
2004
Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling.
BACKGROUND Moxifloxacin is a quinolone antimicrobial that has potent activity against Mycobacterium tuberculosis. To optimize… Expand
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 4
Is this relevant?
Highly Cited
1999
Highly Cited
1999
Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man.
The pharmacokinetics of moxifloxacin and its metabolites M1 (sulpho-compound) and M2 (acyl-glucuronide) were characterized in 12… Expand
  • figure 1
  • table I
  • table II
  • figure 2
  • figure 3
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE